Status:
UNKNOWN
Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Tobacco Use Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit.
Detailed Description
The purpose of this study is to compare the effects of bupropion + placebo to bupropion + naltrexone as treatments to help smokers quit. Bupropion is an FDA-approved medication for smoking cessation t...
Eligibility Criteria
Inclusion
- 18 years and older.
- Smoked at least 10 cigarettes/day for at least 1 year.
- English speaking.
- Females who are of childbearing potential must practice effective contraception and meet the following criteria:
- Are instructed to avoid pregnancy through 30 days after the last dose of study medication.
- Have a negative urine pregnancy test at baseline.
- Agree to use of the birth control methods listed: an oral contraceptive agent, an intrauterine device (IUD), an implantable contraceptive (e.g., Norplant), or an injectable contraceptive (e.g., Depo-Provera) for at least one month prior to entering the study and will continue its use through at least 30 days after the last dose of the study medication. A barrier method of contraception (e.g., condom or diaphragm with spermicide) while participating in the study and 30 days after the last dose of study medication.
- Willingness to reduce alcohol consumption during study to 2 or fewer standard drinks/day (3 oz. of alcohol or two beers (12 oz.), or two 5 oz. glasses of wine).
- Willingness to not use illicit drugs during study period including marijuana.
Exclusion
- Concurrent use of tobacco products (other than cigarettes) or nicotine products.
- Contraindications to use of bupropion (i.e., concurrent use of other forms of bupropion, MAO inhibitors, anti-depressant medication, seizure disorder or any clinical situation that might increase risk for seizures, past head injury, current or prior diagnosis of bulimia or anorexia nervosa; bipolar disorder).
- Contraindications to use of naltrexone (i.e., past history of opioid abuse or dependence or evidence of opioid use in the past 30 days; significant hepatocellular injury as evidenced by liver enzyme levels over 3 times normal limits).
- Use of medications whose metabolism or effects may be adversely altered by bupropion or naltrexone. Medications that contraindicate the use of bupropion include theophylline, procarbazine, carbimazole, nialamide, pargyline, toloxatone, iproniazid, and systemic steroids. Medications that contraindicate the use of naltrexone include opioid analgesics and yohimbine.
- Current use of anti-seizure medications, disulfiram, or any medications that significantly challenge liver functioning.
- Treatment for drug or alcohol dependence during the last year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol.
- Evidence of problem alcohol consumption based on AUDIT.
- Self-reported use of illicit drugs in the past 90 days (including opioids, but excluding marijuana).
- Suicidal or homicidal ideation.
- Current major depression.
- History of bipolar disorder.
- Recent (within twelve months) myocardial infarction.
- Pregnant or lactating or planning pregnancy during treatment period.
- Having plans to leave the immediate geographical area within 9 months.
- Unwillingness or inability to given written informed consent.
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00419731
Start Date
November 1 2006
End Date
July 1 2010
Last Update
December 3 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tobacco Use Research Center, University of Minnesota
Minneapolis, Minnesota, United States, 55414